Skip to Content

Eli Lilly and Co LLY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Lilly's Investor Day Highlights Stronger Than Expected Portfolio, Leading to an FVE Increase

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Eli Lilly hosted an investor day highlighting a better-than-expected outlook, leading us to increase our fair value estimate to $235 from $215. While the company looks very well positioned for industry-leading growth over the next five years, we continue to view the stock as modestly overvalued. Nevertheless, the firm’s robust pipeline and broad portfolio across several therapeutic areas continue to support a strong wide moat.

Read Full Analysis

Company Profile

Business Description

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact
Lilly Corporate Center
Indianapolis, IN, 46285
T +1 317 276-2000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2020
Stock Type Classic Growth
Employees 19,500

Related